Clinical operations guide

Rare-Cancer Trial Readiness: Referral, Testing and Visit Ownership

Plan rare-cancer trial referral, testing, visits, and follow-up around named owners and documented participation barriers.

By Lampgen Clinical Research

· Updated

Lampgen rare-cancer ad shows a referral folder, conceptual pathology slides, an unnumbered calendar, and a travel pass beside an empty clinic chair. It calls for clarifying ownership across referral, testing, and visits. CTA: Discuss site readiness.
AI-generated conceptual editorial illustration; no actual patient, clinical record, study data, facility, or demonstrated result is depicted.
Make the referral-to-visit pathway workable.

Readiness for a rare-cancer trial includes the route from a referral to screening and subsequent visits. A site plan should identify the people, records, tests, and practical arrangements needed at each handoff.

FDA’s December 2025 participation guidance discusses representative enrollment, participation burden, and low-prevalence conditions. The recommendations below are Lampgen’s operational interpretation. They do not establish that a particular service or intervention will improve enrollment.

Map the patient pathway before expanding the site list

Ask where potential participants receive care, how referrals reach the research team, and which outside records or specimens are required for screening. Confirm who requests the material and who follows up when it is delayed. A referral network and a list of activated sites answer different operating questions.

For biomarker requirements, document the laboratory pathway and expected result review. Use the approved protocol, consent, and laboratory procedures. Investigators retain eligibility and medical decisions; a commercial resourcing discussion must not substitute for those judgments.

Review what participation requires in practice

  • Referral: a known research contact and a defined route for outside records.
  • Testing: specimen availability, an authorized request process, and clear report ownership.
  • Visits: appointment capacity, travel demands, work and caregiving constraints, and language needs.
  • Support: the actual study-approved reimbursement or navigation options, explained accurately.
  • Follow-up: an owner and an agreed process when care transfers or a visit is at risk.

Investigate the specific barrier

Consider a hypothetical referral with a suitable clinical history but a pending outside tissue release. The first review should establish whether the delay concerns authorization, material availability, dispatch, laboratory receipt, or result review. Calling the case a recruitment problem does not identify the next action.

Capture the stage, reason, owner, and time to the next decision using authorized study systems. Review whether similar barriers recur across sites or referral sources. Where appropriate and permitted, assess differences in access and follow-up across relevant patient groups without exposing individual identities.

Bring one decision to an advisory discussion

Lampgen Advisory begins with a fixed-scope CRO Oversight Diagnostic for one study and one decision. The deliverable includes an evidence summary, recommended action, proposed owner, and a measure of follow-through. Scope and fee are agreed after the briefing; implementation is a separate decision.

A suitable starting question might be who should own a recurring tissue-request handoff between a CRO, site, and laboratory. That is a concrete operating problem to investigate. Broader recruitment execution, travel funding, laboratory services, and clinical decisions require their own confirmed capabilities, approvals, and scope.

Sources

  1. FDA, Enhancing Participation in Clinical Trials, December 2025
  2. NCI, Biospecimen Best Practices

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?